Systematic literature review of the impact of spinal muscular atrophy therapies on bulbar function

被引:0
作者
McGrattan, Katlyn [1 ]
Walsh, Katie [2 ]
Mehl, Lesa [3 ]
Kaur, Simarjeet [4 ]
Dilly, Keith W. [5 ]
机构
[1] Univ Minnesota, Dept Speech Language Hearing Sci, 164 Pillsbury Dr SE,Shevlin Hall,Suite 225, Minneapolis, MN 55455 USA
[2] Lurie Childrens Hosp, Dept Rehabil, Chicago, IL USA
[3] Novartis, Biomed Res, Cambridge, MA USA
[4] Novartis, Madhapur Hyderabad, India
[5] Novartis Gene Therapies Inc, Bannockburn, IL USA
关键词
bulbar function; disease-modifying treatment; nusinersen; onasemnogene abeparvovec; risdiplam; spinal muscular atrophy; systematic literature review; ABEPARVOVEC GENE-THERAPY; SMN2 COPY NUMBER; ONASEMNOGENE ABEPARVOVEC; OPEN-LABEL; REPLACEMENT THERAPY; RISDIPLAM RG7916; 24-MONTH SAFETY; NUSINERSEN; PART; INFANTS;
D O I
10.1177/22143602241303373
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Improvement and maintenance of bulbar function are important goals of disease-modifying treatments (DMTs) for spinal muscular atrophy (SMA), but standardized and validated measures for assessing bulbar function do not exist, nor does a widely accepted definition of bulbar function in SMA. As such, the impact of DMTs on bulbar function has not yet been comprehensively evaluated.Objective: We conducted a systematic literature review (SLR) to identify evidence about the impact of DMTs for SMA on bulbar function.Methods: We used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines to conduct this review. Embase (R) and MEDLINE (R) databases were searched through August 10, 2023. Eligible studies included patients with SMA who were treated with any DMT and reported bulbar function outcomes. Non-English studies were excluded.Results: We identified 51 studies (across 83 publications) that evaluated SMA DMTs and bulbar function for more than 1600 patients. The ability to feed orally, the ability to tolerate liquids, and the need for nutrition support were commonly reported. Most infants treated with any DMT before SMA symptom onset preserved bulbar function. Infants, children, and adults treated after SMA symptom onset experienced variable results in terms of bulbar function outcomes.Conclusions: The definition and assessment of bulbar function are not standardized. Therefore, the tools, scales, methods, and timing used for bulbar function assessments varied among studies. Larger prospective studies using standardized and age-based assessments with longer follow-up periods are needed to assess the clinical stability of bulbar function for patients with SMA who receive DMTs.
引用
收藏
页码:195 / 217
页数:23
相关论文
共 129 条
[1]   Dysphagia in amyotrophic lateral sclerosis: Quantification of bulbar motor dysfunction [J].
Adamske, Deike ;
Heyduck, Adrienne ;
Weidenmueller, Matthias ;
Goericke, Bettina ;
Frank, Tobias ;
Olthoff, Arno .
JOURNAL OF ORAL REHABILITATION, 2021, 48 (09) :1044-1049
[2]   Health-related quality of life in Thai children with spinal muscular atrophy [J].
Aksaralikitsunti, Manassanan ;
Sanmaneechai, Oranee .
PEDIATRICS AND NEONATOLOGY, 2022, 63 (03) :291-297
[3]   Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy [J].
Al-Zaidy, Samiah ;
Pickard, A. Simon ;
Kotha, Kavitha ;
Alfano, Lindsay N. ;
Lowes, Linda ;
Paul, Grace ;
Church, Kathleen ;
Lehman, Kelly ;
Sproule, Douglas M. ;
Dabbous, Omar ;
Maru, Benit ;
Berry, Katherine ;
Arnold, W. David ;
Kissel, John T. ;
Mendell, Jerry R. ;
Shell, Richard .
PEDIATRIC PULMONOLOGY, 2019, 54 (02) :179-185
[4]   A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy [J].
AlNaimi, Amal ;
Hamad, Sara. G. ;
Mohamed, Reem B. A. ;
Ben-Omran, Tawfeg ;
Ibrahim, Khalid ;
Osman, Mahmoud F. El-Said ;
Abu-Hasan, Mutasim .
PEDIATRIC PULMONOLOGY, 2023, 58 (04) :1004-1011
[5]  
Ambawatte SB., 2022, J Neurol Neurosurg Psychiatry, V93, P72
[6]  
[Anonymous], 2022, Neuromuscul Disord, V32, pS85 S86
[7]   The Burden of Spinal Muscular Atrophy on Informal Caregivers [J].
Aranda-Reneo, Isaac ;
Maria Pena-Longobardo, Luz ;
Oliva-Moreno, Juan ;
Litzkendorf, Svenja ;
Durand-Zaleski, Isabelle ;
Tizzano, Eduardo F. ;
Lopez-Bastida, Julio .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (23) :1-12
[8]  
Babu RR., 2023, BRIT PAED NEUR ASS A
[9]   FIREFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA) [J].
Baranello, G. ;
Bloespflug-Tanguy, O. ;
Darras, B. ;
Day, J. ;
Deconinck, N. ;
Klein, A. ;
Masson, R. ;
Mercuri, E. ;
Dodman, A. ;
El-Khairi, M. ;
Gerber, M. ;
Gorni, K. ;
Kletzl, H. ;
Scalco, R. ;
Servais, L. .
NEUROMUSCULAR DISORDERS, 2020, 30 :S122-S122
[10]   Risdiplam in Type 1 Spinal Muscular Atrophy [J].
Baranello, Giovanni ;
Darras, Basil T. ;
Day, John W. ;
Deconinck, Nicolas ;
Klein, Andrea ;
Masson, Riccardo ;
Mercuri, Eugenio ;
Rose, Kristy ;
El-Khairi, Muna ;
Gerber, Marianne ;
Gorni, Ksenija ;
Khwaja, Omar ;
Kletzl, Heidemarie ;
Scalco, Renata S. ;
Seabrook, Timothy ;
Fontoura, Paulo ;
Servais, Laurent .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (10) :915-923